[go: up one dir, main page]

KR890014095A - 방출 제어형 약제 및 그의 제조방법 - Google Patents

방출 제어형 약제 및 그의 제조방법 Download PDF

Info

Publication number
KR890014095A
KR890014095A KR1019890004085A KR890004085A KR890014095A KR 890014095 A KR890014095 A KR 890014095A KR 1019890004085 A KR1019890004085 A KR 1019890004085A KR 890004085 A KR890004085 A KR 890004085A KR 890014095 A KR890014095 A KR 890014095A
Authority
KR
South Korea
Prior art keywords
formulation
group
polymer material
hydrophobic
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019890004085A
Other languages
English (en)
Other versions
KR950007202B1 (ko
Inventor
마사요시 사메지마
가즈오 노다
요시유끼 히라가와
히로유끼 요시노
Original Assignee
아다찌 게이지로
다나베 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=13722933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR890014095(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아다찌 게이지로, 다나베 세이야꾸 가부시끼가이샤 filed Critical 아다찌 게이지로
Publication of KR890014095A publication Critical patent/KR890014095A/ko
Application granted granted Critical
Publication of KR950007202B1 publication Critical patent/KR950007202B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음.

Description

방출 제어형 약제 및 그의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 제약적 유효성분을 함유한 코어 물질 및 소수성 고분자 또는 소수성 중합체 물질과 친수성 중합체 물질의 다공성 피막으로 되고, 상기 코어가 상기 다공성 피막으로 피복된 방출 제어형 제제.
  2. 제1항에 있어서, 상기 다공성 피막이 약 0.4 내지 0.9의 다공도를 갖는 제제.
  3. 제2항에 있어서, 상기 다공성 피막이 약 0.5 내지 0.85의 다공도를 갖는 제제.
  4. 제1항에 있어서, 상기 다공성 피막이 소수성 중합체 물질로 된 제제.
  5. 제1항에 있어서, 상기 다공성 피막이 소수성 중합체 물질 및 친수성 중합체 물질로 된 제제.
  6. 제5항에 있어서, 상기 다공성 피막이 소수성 중합체 물질의 1중량부에 대해서 친수성 고분자 물질 0.05 내지 0.5중량부로 되는 제제.
  7. 제5항에 있어서, 상기 소수성 중합체 물질이 적어도 셀룰로오스 에테르, 셀룰로오스 에스테르, 폴리비닐 에스테르 및 4차 암모늄 알킬기를 가진 아크릴산으로 되는 군중에서 선택된 것인 제제.
  8. 제6항에 있어서, 상기 소수성 물질이 적어도 셀룰로오스 에테르, 셀룰로오스 에스테르, 폴리비닐 에스테르 및 4차 암모늄 알킬기를 가진 아크릴형 중합체로 되는 군중에서 선택되고, 소수성 물질이 수용성 중합체 물질, 장 용해성 중합체 물질, 위 용해성 중합체 및 장 용해성 중합체 물질과 위 용해성 중합체 물질로 되는 군중에서 선택한 것인 제제.
  9. 제8항에 있어서, 수용성 중합체 물질이 임의로 황산기를 갖는 다당류, 히드록시알킬기를 갖는 다당류,카르복시알킬기를 갖는 다당류, 메틸 셀룰로오스 폴리비닐 피롤리딘, 폴리비닐 알콜 및 폴리에틸렌 글리콜로 되는 군중에서 선택된 적어도 하나이고, 장 용해성 중합체 물질이 카르복시알킬 셀룰로오스, 이염기산의 모노에스테르 결합을 갖는 셀룰로오스 유도체, 말레산 -비닐 공중합체 및 아크릴산 형 중합체로 되는 군중에서 선택된 적어도 하나이고, 위 용해성 중합체 물질이 일 - 또는 이 - 치환 아미노기를 갖는 셀룰로오스 유도체 및 일치환 아미노기를 갖는 아크릴산 중합체로 되는 군중에서 선택된 적어도 하나이고, 장 용해성 및 위용해성 중합체 물질이 비닐 피리딘 - 아크릴산형 공중합체, 일 - 또는 이 - 치환 아미노기를 가지는 카르복시메틸 다당류 및 폴리비닐 아미노산형 유도체로 되는 군중에서 선택된 적어도 하나인 제제.
  10. 제9항에 있어서, 상기 다공성 피막이 소수성 중합체 물질 및 수용성 중합체 물질 또는 소수성 중합체 물질 및 장내성 중합체 물질로 되는 제제.
  11. 제10항에 있어서, 상기 다공성 피막이 에틸 셀룰로오스 및 히드록시프로필 셀룰로오스인 제제.
  12. 제11항에 있어서, 상기 다공성 피막이 에틸 셀룰로오스 및 히드록시프로필 셀룰로오스로 구성되고, 유기산이 코어내에서 제약 유효 성분과 함께 함유된 것인 제제.
  13. 제12항에 있어서, 상기 유기산이 숙신산인 제제.
  14. 제약 유효 성분을 함유한 코어 물질을 소수성 중합체 물질 또는 소수성 중합체 물질과 친수성 중합체 물질을 함유하는 물 - 유기 용매 혼합물로 분무 코팅시켜서 코어물질의 표면에 상기 중합체 물질(들)로 된 다공성 피막을 형성시키는 것으로 되는 방출 제어형 제제를 제조하는 방법.
    ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019890004085A 1988-03-31 1989-03-30 방출 제어형 약제 및 그의 제조방법 Expired - Fee Related KR950007202B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP80604/1988 1988-03-31
JP8060488 1988-03-31

Publications (2)

Publication Number Publication Date
KR890014095A true KR890014095A (ko) 1989-10-21
KR950007202B1 KR950007202B1 (ko) 1995-07-04

Family

ID=13722933

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890004085A Expired - Fee Related KR950007202B1 (ko) 1988-03-31 1989-03-30 방출 제어형 약제 및 그의 제조방법

Country Status (21)

Country Link
US (1) US5068112A (ko)
EP (1) EP0335560B2 (ko)
KR (1) KR950007202B1 (ko)
AT (1) ATE91888T1 (ko)
AU (1) AU610711B2 (ko)
BG (1) BG50712A3 (ko)
CA (1) CA1339078C (ko)
DE (1) DE68907762T3 (ko)
DK (1) DK156289A (ko)
ES (1) ES2059729T5 (ko)
FI (1) FI101344B (ko)
FR (1) FR2629344B1 (ko)
HK (1) HK76195A (ko)
HU (1) HU201882B (ko)
IE (1) IE64348B1 (ko)
IL (1) IL89695A0 (ko)
NO (1) NO178136C (ko)
PH (1) PH25791A (ko)
PT (1) PT90153B (ko)
RU (1) RU1836083C (ko)
ZA (1) ZA892131B (ko)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101344B (fi) † 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseut tisesti aktiivista ainetta
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US6350462B1 (en) * 1990-12-26 2002-02-26 Olympus Optical Co., Ltd. Hollow porous ceramic carrier for embedding in patient for sustained medicament release and method of preparation thereof
JP2538134B2 (ja) * 1991-04-08 1996-09-25 田辺製薬株式会社 徐放性製剤およびその製造法
EP0585355B1 (en) * 1991-05-20 1995-03-22 Marion Laboratories, Inc. Multi-layered controlled release formulation
EP0520119A1 (de) * 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
GB9117361D0 (en) * 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US5523095A (en) * 1993-12-15 1996-06-04 Eastman Chemical Company Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
US5536505A (en) * 1993-12-15 1996-07-16 Eastman Chemical Company Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends
ES2120354B1 (es) * 1996-02-12 1999-07-01 Univ Sevilla Dispositivo terapeutico para direccionar farmacos hacia el tramo del tracto gastrointestinal deseado en funcion de las caracteristicas fisicoquimicas del mismo.
DE19628776A1 (de) * 1996-07-17 1998-01-22 Bayer Ag Oral applizierbare Granulate von Hexahydropyrazinderivaten
US20030100532A1 (en) * 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
BR9802915A (pt) * 1997-09-12 2000-01-11 Oscar Gold Procedimento para formar composições farmaceuticas em pilulas ou granulos substancialmente esfericos, de ação controlada e continuada, contendo como agente ativo o (7-bromo-1,3-diidro-5-(2-piridninilo)-2h-1,4-benzodiazep ina-2(1h)-um)
JP2001522833A (ja) 1997-11-10 2001-11-20 ジー・ディー・サール・アンド・カンパニー 多剤耐性を治療するためのアルキル化イミノ糖類の使用
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
TR200002323T2 (tr) 1998-02-12 2000-12-21 G.D. Searle & Co. Hepatit virüs enfeksiyonlarının tedavi edilmesi için N-ikameli-1,5-dideoksi 1,5-imino-D-glusitol bileşiklerinin kullanımı
DK1067910T3 (da) 1998-04-03 2004-10-04 Egalet As Komposition med styret afgivelse
DE60039729D1 (de) * 1999-02-12 2008-09-11 United Therapeutics Corp N-(8,8,8-Trifluorooctyl)-1,5-dideoxy-1,5-imino-D-glucitol zur Behandlung von Hepatitis-Virus-Infektionen
JP2003505501A (ja) 1999-02-12 2003-02-12 ジー・ディー・サール・アンド・カンパニー 肝炎ウィルス感染の処置のためのグルカミン化合物
SE9903879D0 (sv) * 1999-10-28 1999-10-28 Ethical Pharmaceuticals Sweden Multipor food protection
WO2001047498A2 (en) 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
EP1252887A4 (en) 2000-01-27 2009-07-29 Mitsubishi Tanabe Pharma Corp EXTENDED RELEASE PREPARATION AND METHOD FOR MANUFACTURING THE SAME
US20050119310A1 (en) * 2000-02-14 2005-06-02 Mueller Richard A. Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
US20040208936A1 (en) * 2002-07-22 2004-10-21 Roland Chorin Novel compositions
WO2004041252A1 (en) 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
EP1607092A4 (en) * 2003-03-17 2010-12-15 Takeda Pharmaceutical COMPOSITIONS WITH CONTROLLED RELEASE
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
ATE399538T1 (de) 2003-03-26 2008-07-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
US7115283B2 (en) * 2003-05-06 2006-10-03 Access Business Group International Llc Preparations for sustained release of nutraceuticals and methods of controllably releasing nutraceuticals
ATE341312T1 (de) * 2003-05-20 2006-10-15 Ethypharm Sa Orale pharmazeutische zusammensetzung mit verzögerter freisetzung
FR2855412B1 (fr) * 2003-05-27 2007-05-25 Menvielle Bourg Fabienn Joanny Composition a liberation prolongee de magnesium, et son application dans le domaine therapeutique, cosmetique et nutritionnel
JP2007520421A (ja) * 2003-06-26 2007-07-26 コリア リサーチ インスティテュート オブ ケミカル テクノロジー 経口投与用放出制御型薬物送達システム
EP1652514A1 (en) * 2003-08-04 2006-05-03 Eisai Co., Ltd. At-use dispersed preparation
KR100615952B1 (ko) 2004-05-27 2006-08-28 한국화학연구원 서방형 약물 전달 시스템
JP5161075B2 (ja) * 2005-06-03 2013-03-13 エガレット エイ／エス 分散媒体の第１フラクションとマトリックスの第２フラクションを有し、第２フラクションが胃腸の液体に少なくとも部分的に最初に曝される固形の医薬組成物
RU2309732C1 (ru) 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
ATE525065T1 (de) * 2006-07-10 2011-10-15 Pfleger R Chem Fab Pharmazeutische zubereitung für die orale verabreichung mit gesteuerter wirkstofffreisetzung im dünndarm und verfahren zu ihrer herstellung
NZ577560A (en) * 2007-01-16 2012-01-12 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008094877A2 (en) * 2007-01-30 2008-08-07 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
WO2008112388A1 (en) 2007-03-14 2008-09-18 Drugtech Corporation Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
PL2187873T3 (pl) 2007-08-13 2019-01-31 Abuse Deterrent Pharmaceutical Llc Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania
FR2931359B1 (fr) * 2008-05-20 2012-12-21 Menvielle Bourg Fabienne Joanny Utilisation d'une matrice pour administration orale de magnesium a liberation prolongee, et composition contenant cette matrice
FR2931361B1 (fr) * 2008-05-20 2012-08-31 Menvielle Bourg Fabienne Joanny Systeme a base de magnesium et son utilisation en cosmetique
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
ES2440393R1 (es) 2010-07-15 2014-10-10 Oleg Iliich Epshtein Un método para aumentar el efecto de una forma activada potenciada de un anticuerpo
KR20150059167A (ko) 2012-07-06 2015-05-29 에갈렛 리미티드 제어된 방출을 위한 남용 제지 약학적 조성물
MX2015013231A (es) 2013-03-15 2016-06-07 Inspirion Delivery Technologies Llc Composiciones que disuaden el abuso y metodos de utilizacion.
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
WO2017058869A1 (en) 2015-09-29 2017-04-06 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2223896A1 (de) † 1972-05-17 1973-11-29 Sanol Arznei Schwarz Gmbh Verfahren zum ueberziehen von feinteiligen arzneimitteln
DD146547A5 (de) † 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
US4377568A (en) † 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) † 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS5989622A (ja) † 1983-09-29 1984-05-23 Furointo Sangyo Kk 公害を生じないフイルムコ−テング法
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
EP0162492B1 (en) * 1984-04-11 1989-08-02 Thiemann Arzneimittel GmbH Dosage units for controlled release of active material
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
US4629619A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4663147A (en) * 1985-09-03 1987-05-05 International Minerals & Chemical Corp. Disc-like sustained release formulation
LU86099A1 (fr) * 1985-09-30 1987-04-02 Pharlyse Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant
US5254347A (en) † 1988-03-31 1993-10-19 Tanabe Seiyaku Co., Ltd. Controlled release pharmaceutical preparation and method for producing the same
FI101344B (fi) † 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseut tisesti aktiivista ainetta

Also Published As

Publication number Publication date
DE68907762D1 (de) 1993-09-02
ATE91888T1 (de) 1993-08-15
EP0335560B2 (en) 2002-01-23
HK76195A (en) 1995-05-26
HU201882B (en) 1991-01-28
PT90153A (pt) 1989-11-10
DE68907762T3 (de) 2003-11-20
HUT50050A (en) 1989-12-28
PH25791A (ko) 1991-11-05
FI101344B1 (fi) 1998-06-15
FI891163L (fi) 1989-10-01
DK156289D0 (da) 1989-03-30
NO178136B (no) 1995-10-23
EP0335560A2 (en) 1989-10-04
ES2059729T3 (es) 1994-11-16
DK156289A (da) 1989-10-01
AU3227389A (en) 1989-10-05
US5068112A (en) 1991-11-26
KR950007202B1 (ko) 1995-07-04
ZA892131B (en) 1989-11-29
RU1836083C (ru) 1993-08-23
NO891052L (no) 1989-10-02
AU610711B2 (en) 1991-05-23
IE891006L (en) 1989-09-30
CA1339078C (en) 1997-07-29
IE64348B1 (en) 1995-07-26
ES2059729T5 (es) 2002-09-16
FI891163A0 (fi) 1989-03-10
EP0335560A3 (en) 1990-12-27
FR2629344B1 (fr) 1994-09-16
FI101344B (fi) 1998-06-15
PT90153B (pt) 1994-07-29
BG50712A3 (bg) 1992-10-15
IL89695A0 (en) 1989-09-28
NO891052D0 (no) 1989-03-13
NO178136C (no) 1996-01-31
FR2629344A1 (fr) 1989-10-06
EP0335560B1 (en) 1993-07-28
DE68907762T2 (de) 1993-11-11

Similar Documents

Publication Publication Date Title
KR890014095A (ko) 방출 제어형 약제 및 그의 제조방법
KR970005279A (ko) 소화관의 하부 부분에서 방출될 수 있는 피복 캡슐 형태의 약학 제제
US4433076A (en) Coating agent for medicaments and methods for making and using the same
KR920702618A (ko) 약제학적 제형
JP2529941B2 (ja) 薬物結腸放出用浸透構成体
AU686168B2 (en) Controlled release formulations coated with aqueous dispersions of acrylic polymers
US6221395B1 (en) Controlled release pharmaceutical tablets containing an active principle of low water solubility
KR930003114B1 (ko) 2상성의 방출 단면을 가진 제어 방출되는 경구용 제제의 제조방법
FI109451B (fi) Menetelmä lääkeaineen annosteluvälineen valmistamiseksi, joka tuottaa in situ ja vapauttaa kontrolloidusti lääkedispersion
KR920002135A (ko) 대장에서만 방출할수 있는 피복시킨 고체 약물형태
KR950701214A (ko) 눈에 투여를 위한 약제학적 투약 형태 및 그 제조방법(galenic form for ocular administraion and process for the preparation of same)
KR910011243A (ko) 서방성 약제 용량 단위
KR950005301A (ko) 방출 개시 제어 및 방출 속도 제어형 제제
RU99108461A (ru) Лекарственная форма для перорального введения с отложенным немедленным высвобождением и способ ее приготовления
DE58901990D1 (de) Feste pharmazeutische retardform.
DE69816951D1 (de) Zubereitung enthaltend Cefaclor oder Cephalexin mit modifizierter Freisetzungsmatrix
GB1567727A (en) Constant rate release tablets
IL92994A (en) Combined immediate and sustained release gemfibrozil pharmaceutical composition
US4088798A (en) Methods for the preparation of controlled gastric residence time medicament formulations
ES2104044T3 (es) Capsulas blandas revestidas entericas y metodo para su produccion.
KR900017572A (ko) 필름 피복 정제
JPS56127322A (en) Enteric coating material composition for solid drug
ES462418A1 (es) Un procedimiento para la preparacion de composiciones biolo-gicamente activas.
NO160901C (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat i form av en polyakrylatfilm.
IE882898L (en) Solubility modulated drug delivery device

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20040624

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20050705

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20050705

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000